

Kromek Group PLC

05:00 10 Dec 2018

Kromek deepens relationship with DARPA as it expands reach into bio-threat detection

Kromek Group PLC (LON:KMK) has further strengthened its relationship with the Defense Advanced Research Projects Agency (DARPA), part of the US Department of Defense, with a 12-month contract for biological threat detection systems carrying a value of US\$1.99m.

READ: Kromek jumps as it secures bio-threat detection contract with DARPA
The contract, which began on 10 December, is to develop a proof-of-concept device for a vehicle-mounted biological-threat identifier but has potential to be extended to a multi-year project to develop a fully deployable system.

'Dirty Bomb' detectors

The bio-threat detection deal is the latest win in a relationship with DARPA that the company has cultivated throughout the year.

In March, Kromek was awarded an extension to a high-volume production contract with DARPA, worth around US\$1.6m, to enhance its D3S equipment that is already deployed at the agency.

D3S is part of the radiation detection range of Kromek's products and was previously used at a NATO summit in July as part of the meeting's security arrangements.

Inroads at DTRA

Aside from DARPA, the company also clinched a funding deal in September with DTRA, the Defense Threat Reduction Agency, also a part of the DoD.

READ: Kromek secures US\$1.8m from US defence department to develop radiation detection device

The US\$1.8m in funding formed part of a previous agreement with DTRA in which Kromek will develop a next-generation radionuclide identification device for detecting radioactive substances.

The process involves the use of Kromek's D3S platform to develop a next-generation, ruggedised small form factor for use in the military field.

Baggage scanning success

The firm is also seeing progress with its CZT range of detector modules, which it agreed to customise for baggage screening systems in a five-year, US\$7.8m deal in November.

READ: Kromek surges as it inks contract to supply technology for baggage scanning systems

CZT stands for cadmium zinc telluride, a semiconductor used for x-ray and gamma radiation detection that can operate at room temperature. The deal itself is with an existing client, an x-ray systems maker.


Medical contract wins

The firm's CZT tech has also been picked up in the medical sector, receiving two orders in August that had a combined

Price: 20.8

Market Cap: £71.68 m

1 Year Share Price Graph



October 2018 April 2019 October 2019

Share Information

Code: KMK

Listing: AIM

52 week High Low
31.9459 20.5

Sector: Hardware & electrical equipment

Website: www.kromek.com

Company Synopsis:

Kromek Group plc is a leading developer of radiation detection solutions based on high performance sensor materials, primarily cadmium zinc telluride (CZT), for applications within the medical, nuclear and security screening markets.

action@proactiveinvestors.com

value of around US\$1mln.

READ: Kromek medical division lands two new contracts worth US\$1mln

The orders included one from an equipment manufacturing customer has placed a US\$700,000 order for Kromek's CZT detectors to be used in nuclear medicine.

The other was a repeat contract in the bone mineral densitometry market for CZT detectors worth US\$340,000.

Cancer to TNT

Headquartered in County Durham, Kromek designs, develops, and produces x-ray and gamma-ray imaging and radiation detection products for the medical, security screening, homeland security and civil nuclear markets.

Its products provide high-resolution information on material composition and structure.

Practically, the technology can be used to identify anything from cancerous tissue through to hazardous materials such as explosives and radioactive matter.

Kromek provides customers with radiation detector materials used for devices as well as finished products such as detectors.

As well as operations in the UK, it has bases in California and Pennsylvania in the US.

It sells directly to equipment manufacturers and via distributors.

Monday's was one of a number of new contracts wins for the business, which included two new deals with the US government to supply radiation detection equipment.

With shares trading at around 26p, the company carries a market cap of £66.4mln.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Kromek Group PLC named herein, including the promotion by the Company of Kromek Group PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five

Thousand

dollars

(\$25,000).